




ECW

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification<sup>5</sup> : C07D 221/18, 401/04, 401/06 C07D 409/04, 409/06 A61K 31/44, 31/495, 31/535</p>	<p>A1</p>	<p>(11) International Publication Number: WO 92/00281 (43) International Publication Date: 9 January 1992 (09.01.92)</p>
<p>(21) International Application Number: PCT/US91/04364 (22) International Filing Date: 19 June 1991 (19.06.91) (30) Priority data: 543,596 26 June 1990 (26.06.90) US (71) Applicant: RESEARCH CORPORATION TECHNOLOGIES, INC. [US/US]; 6840 East Broadway Boulevard, Tucson, AZ 85710-2815 (US). (72) Inventors: ALBERTS, David, S. ; 250 North Indian House Road, Tucson, AZ 85711 (US). DORR, Robert, T. ; 1130 South Avendia Conale, Tucson, AZ 85718 (US). REMERS, William, A. ; 5022 East Calle Guebabi, Tucson, AZ 85718 (US). SAMI, Salah, M. ; 827 East Alturas, Tucson, AZ 85719 (US).</p>		<p>(74) Agent: SCOTT, Anthony, C.; Scully, Scott, Murphy &amp; Presser, 400 Garden City Plaza, Garden City, NY 11530 (US). (81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).  Published With international search report.</p>

*Handwritten signature/initials in a circle*

(54) Title: 1,2-DIHYDRO-3H-DIBENZISOQUINOLINE-1,3-DIONE ANTICANCER AGENTS



(57) Abstract

This invention relates to a compound useful for the treatment of tumors having formula (I), wherein  $R_8$ ,  $R_6$  and  $R_{10}$  are independently hydrogen, lower alkyl, aryl, lower alkanoyl, formyl, halogen, nitro,  $NR_2R_3$ ,  $OR_1$ , or  $SR_1$ , methoxy, hydroxy, cyano  $CO_2H$ ,  $SO_2NR_1R_2$ , or  $CONR_1R_2$ ;  $R_1$ ,  $R_2$  and  $R_3$  are independently hydrogen, lower alkyl, aryl lower alkyl, aryl, formyl or lower alkanoyl;  $R_9$ ,  $R_{11}$ ,  $R_{10}$  and  $R_7$  are independently hydrogen, or lower alkyl or  $R_9$  and  $R_{11}$  taken together with the carbon atoms to which they are attached form a phenyl group or  $R_9$  and  $R_{10}$  taken together with the carbon atoms to which they are attached form a phenyl group or  $R_7$  and  $R_{10}$  taken together with the carbon atoms to which they are attached from a phenyl group; A is  $(CR_4R_5)_n$ , lower cycloalkyl or aryl or a chemical bond; each  $R_4$  and  $R_5$  are independently hydrogen or lower alkyl;  $R_{12}$  and  $R_{13}$  are independently hydrogen, or lower alkyl which is unsubstituted or substituted with hydroxy, mercapto, lower alkoxy, lower alkylcarbonyloxy, carboxy, or carbloweralkoxy or  $R_{12}$  and  $R_{13}$  taken together with the nitrogen to which they are attached form a 3-6-membered heterocyclic ring; D is a chemical bond or taken together with  $NR_{12}$  form a 5 or 6-membered heterocyclic ring;  $n_1$  and  $n_2$  are independently 0, 1 or 2; and  $n_3$  is 0, 1, 2, 3, 4 or 5.

**THIS PAGE BLANK (USPTO)**

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TC	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				


- 1 -

## 1,2-DIHYDRO-3H-DIBENZISOQUINOLINE -1,3-DIONE ANTICANCER AGENTS

This invention is directed towards derivatives of azonafide having improved anti-tumor activity.


The search for compounds showing anti-tumor activity has, in recent years, included fused ring structures such as derivatives of anthracene, and heterocyclics such as isoquinoline and acridine. The first anthracene derivative to show promise was 2,2'-(9,10 anthracene-dimethylene)bis-(2-thiopseudourea) dihydrochloride, which unfortunately suffered from phototoxicity (U. S. Patent No. 3,190,795 and Carter, Cancer Chemother. Rep., 1, 153-163, 1968). See also, Frei, E. III, et al., Cancer Chemother Rep., 55, 91-97 (1971).

Furthermore, Brana, et al. in Cancer Chemother Pharmacol, 4, 61-66 (1980) and in Eur. J. Med., 16, 207-212 (1981) disclose 2- and 5- substituted benz[de]isoquinoline-1,3-diones having the formula:




wherein X is H, NO<sub>2</sub>, NH<sub>2</sub>, Cl, OH, NHCO<sub>2</sub>Et, OCH<sub>3</sub>, NHCOCH<sub>3</sub> or t-Bu and Y is a disubstituted amine, OH, OCH<sub>3</sub>, CH(CH<sub>3</sub>)<sub>2</sub>, SH or NHCOCH<sub>3</sub> and n is an integer ranging from zero to three. It is alleged that the compounds therein inhibit Hela Cells.

Miller, et al. in U. S. Patent No. 4,108,896 discloses compounds having the formula:



wherein A is a straight or branched alkylene chain having from 1 to 6 carbon atoms;  $R_1$  and  $R_2$  are each selected from the group consisting of hydrogen, lower alkyl having from 1 to 6 carbon atoms, cycloalkyl having from 3 to 6 carbon atoms, alkenyl having from 3 to 6 carbon atoms in which the unsaturation is in a position other than in the 1-position of the alkenyl group, or  $R_1$  and  $R_2$  taken together with the nitrogen atom to which they are attached, represent the pyrrolidinyl, piperidino or morpholino radical;  $R_3$  is selected from the group consisting of hydrogen and the radical,



with the proviso that one and only one such R group is hydrogen.

The compounds are disclosed as having use as antiviral agents.

However, the teachings of the references discussed hereinabove are limited to the anthracene and isoquinoline derivatives discussed therein. None of these references suggest that the dibenzisoquinoline 1,3-diones of the present invention would be useful and effective as anti-tumor agents.


1           Amonafide (NSC 308847) is an isoquinoline dione  
derivative having anti-tumor activity. More specifically,  
2           amonafide, amino-N-dimethylaminoethylbenz[de]isoquinoline,  
has undergone extensive tests for its anti-tumor activity.  
3           The National Cancer Institute prepared and distributed a  
brochure summarizing the anti-tumor activity of amonafide in  
4           1984. Although the level of activity found for amonafide  
was and continues to be of high interest, this material does  
5           have significant deficiencies which indicate the continuing  
need for agents with improved properties. In the first  
6           place, amonafide has produced substantial myelotoxicity  
leading to some deaths in patients receiving five daily  
7           doses of the drug. In addition, this report showed that  
amonafide had only moderate activity in leukemia models in  
8           mice. Also, it showed that amonafide has no activity in  
human tumor xenographs in mice with colon, lung and mammary  
9           cancers. Thus, while amonafide showed significant activity,  
it does not have a substantially broad spectrum of activity  
10          in murine tumor models.

11          Another group has shown that amonafide or nafidimide  
have poor activity when tested in primary human solid tumors  
12          in vitro. See, Ajani, J. A. et al., Invest New Drugs, 6,  
79-83 (1988).

13          In contrast, we have found that compounds based on  
anthracene instead of naphthalene show surprising anti-tumor  
14          activity.

15          The present invention is directed to 1,2-dihydro-3H-  
16          dibenzisoquinoline-1,3-dione derivatives which exhibit  
anti-tumor activity and are useful as anti-cancer agents.

More particularly, the present invention is directed to compounds of the formula:



wherein

$R_8$ ,  $R_{10}$  and  $R_6$  are independently hydrogen, lower alkyl, aryl, lower alkanoyl, formyl, halogen, nitro,  $NR_2R_3$ ,  $OR_1$ , cyano,  $CO_2H$ ,  $CONR_1R_2$ ,  $SO_2NR_1R_2$  or  $SR_1$ ;

$R_1$ ,  $R_2$  and  $R_3$  are independently hydrogen, lower alkyl, aryl lower alkyl, aryl, formyl or lower alkanoyl;

$R_9$ ,  $R_{11}$ , and  $R_7$  are independently hydrogen or lower alkyl or

$R_9$  and  $R_{11}$  taken together with the carbon atoms to which they are attached form a phenyl ring, or

$R_9$  and  $R_{10}$  taken together with the carbon atoms to which they are attached form a phenyl ring or

$R_7$  and  $R_{10}$  taken together with the carbon atoms to which they are attached form a phenyl ring;

A is  $(CR_4R_5)_3$ , lower cycloalkyl, aryl, or a chemical bond,

each  $R_4$  and  $R_5$  are independently hydrogen or lower alkyl;

$R_{12}$  and  $R_{13}$  are independently hydrogen or lower alkyl which is unsubstituted or substituted with hydroxy, mercapto, lower alkoxy, lower alkylcarbonyloxy, carboxy or carbloweralkoxy, or  $R_{12}$  and  $R_{13}$  taken together with the nitrogen atom to which they are attached form a 3 to 6-membered heterocyclic ring;


D is a chemical bond, or taken together with  $NR_{12}$  form a 5 or 6-membered heterocyclic ring;

$n_1$  and  $n_2$  are independently 0, 1, or 2 and

$n_3$  is 0, 1, 2, 3, 4 or 5.

These compounds are useful in treating cancer in animals, including mammals by administering to said animals, an effective anti-tumor dose of said compounds.

As indicated hereinabove, the present invention is directed to 1,2-dihydro-3H-dibenz(deh)isoquinoline-1,3-dione derivatives. Since the ring structure may have substituents at various positions, to aid in the understanding of the various derivatives, the nomenclature with respect to the dibenzisoquinoline structure is as indicated hereinbelow:



As used herein, the term "alkyl", when used alone or in combination, consists of a carbon chain containing from one to six carbon atoms. The alkyl groups may be a straight chain or a branched chain. It includes such groups as methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, iso-butyl, t-butyl, n-pentyl, amyl, n-hexyl, and the like. The preferred alkyl group is methyl.



1 The term "aryl", when used alone or in combination,  
consists of an aromatic monocyclic or bicyclic structure  
having 6 to 10 ring carbon atoms and up to a total of 15  
total carbon atoms. It includes such structures as phenyl,  
-naphthyl or  $\beta$ -naphthyl. The preferred aryl group is  
phenyl.

5 The term "aryl lower alkyl", is an aryl group attached  
to the dibenzisoquinoline ring through an alkylene group,  
such as methylene, ethylene, propylene and the like.  
Examples include benzyl, phenethyl and the like. The  
preferred aryl lower alkyl group is benzyl.

10 "Alkylene", as used herein, whether alone or in  
combination, is an alkyl group attached to the principal  
chain of the compound of the present invention through two  
carbon linkages. This group may be straight chained or  
branched. It includes such groups as methylene ( $-\text{CH}_2-$ ),  
15 ethylene ( $-\text{CH}_2-\text{CH}_2-$ ), propylene ( $-\text{CH}_2-\text{CH}_2-\text{CH}_2-$ ),  
isopropylene ( $-\text{CH}-\text{CH}_2-$ ), isobutylene, butylene,  
 $\left( \begin{array}{c} \text{CH}_3 \end{array} \right)$   
sec-butylene, and the like.

20 As used herein, the term "alkanoyl" is an alkyl group  
substituted by an oxo group. The oxo group can be  
substituted at any carbon atom, but is preferred at the  
1-position, i.e., the carbon atoms directly attached to the  
dibenzisoquinoline ring structure. This group includes  
25 acetyl, propanoyl, butanoyl, and the like. The preferred  
group is acetyl.


Halogen, as used herein, refers to fluorine, chlorine,  
bromine or iodine.

30 The term "lower cycloalkyl" refers to a monocyclic alkyl  
group containing from 3 to 6 ring carbon atoms and up to a  
total of 10 carbon atoms. This group includes cyclopropyl,  
cyclobutyl, cyclopentyl, cyclohexyl and the like. The  
preferred cycloalkyl groups are cyclopentyl and cyclohexyl.

The heterocyclic rings as defined herein are 3-6 membered rings containing at least one oxygen, sulfur and nitrogen ring atom and up to a total of 4 ring heteroatoms. It is preferred, however, that there may be one or two ring heteroatoms. Especially preferred is one ring heteroatom. The preferred heteroatom is nitrogen. The heterocyclic ring may be completely saturated or partially unsaturated or may be heteroaromatic. It is preferred that the heterocyclic ring contain 5 or 6 ring atoms. Examples include thiophene, furan, pyran, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, isothiazole, furazan, isoxazole, imidazolidine, imidazoline, pyrazolidine, piperidine, morpholine, pyrrolidine, tetrahydrofuran, tetrazole, and the like. The preferred heterocyclic groups are piperidine, pyrrolidine, piperazine, or imidazole, pyridyl, or aziridinyl. The especially preferred heterocyclic groups are piperidine and pyrrolidine.


As indicated in the above formula, the side chain "A-D-NR<sub>12</sub>R<sub>13</sub>" is attached to the nitrogen at the 2-position of the dibenzisoquinoline-1,3-diones. This group can be a straight chain, such as (CH<sub>2</sub>)<sub>n</sub>NR<sub>12</sub>R<sub>13</sub>, wherein n is 1-5 and R<sub>12</sub> and R<sub>13</sub> are each lower alkyl or hydrogen. Alternatively, R<sub>12</sub> and R<sub>13</sub> may with the nitrogen to which they are attached form a 3 to 6 membered ring, such as pyrrolidine or piperidine.

In addition, the NR<sub>12</sub> group together with D may form a 5 or 6 membered nitrogen heterocyclic ring, such as a piperidine or pyrrolidine, e.g.,




wherein R<sub>13</sub> is as defined hereinabove.


The groups  $R_9$  and  $R_{11}$  may together form an aryl ring.  
 For example, if  $R_9$  and  $R_{11}$  form a phenyl ring, the compound  
 of Formula I becomes:



Alternatively,  $R_{10}$  and  $R_9$  may together form an aryl  
 ring, e.g., phenyl ring. Then the compound of Formula I  
 will become:




Furthermore, when  $R_7$  and  $R_{10}$  taken together with the carbon atoms to which they are attached form an aryl group, such as phenyl, the compound of Formula I becomes:



In all of these structures hereinabove,  $R_{11}$ ,  $R_6$ ,  $R_9$ ,  $R_{10}$ ,  $R_7$ ,  $R_8$ ,  $A$ ,  $D$ ,  $R_{12}$ ,  $R_{13}$ ,  $n_1$  and  $n_2$  are as defined hereinabove.

A preferred embodiment of the present invention has the formula:



wherein  $R_6$ ,  $A$ ,  $D$ ,  $R_{12}$  and  $R_{13}$  are as defined hereinabove.

It is preferred that  $R_6$  is hydrogen, amino, chloro or nitro.

Moreover, it is preferred that  $R_6$  is substituted on the

8-, 9, 10- or 11-position of the dibenzisoquinoline-1,3-dione of the present invention.


The preferred  $R_1$ ,  $R_2$  and  $R_3$  groups are hydrogen or methyl. Therefore, it is preferred that  $NR_2R_3$ ,  $OR_1$ , and  $SR_1$  groups are amino, hydroxy or mercapto.

It is preferred that  $\Lambda$  is alkylene containing from 1-4 carbon atoms, aryl or a chemical bond. It is especially preferred that the alkylene group is of the formula  $(CH_2)_{n_3}$ , wherein  $n_3$  is 2-3. The preferred aryl group is phenyl.

The most preferred  $R_{12}$  and  $R_{13}$  groups are lower alkyl or lower alkyl substituted with hydroxy. When  $NR_{12}$  does not form a ring with D, it is preferred that the  $R_{12}$  and  $R_{13}$  groups be the same. The most preferred  $R_{12}$  and  $R_{13}$  groups are methyl or  $CH_2CH_2OH$ .

It is preferred that  $R_{10}$  is hydrogen, methyl, methoxy, chloro or hydroxy.


An especially preferred embodiment of the present invention has the formula:



wherein  $R_{12}$ ,  $R_{13}$ ,  $n_3$ ,  $R_6$  and  $R_{10}$  are as defined hereinabove, and  $n_4$  is 0 or 1.

The compounds of the present invention can be prepared by art recognized techniques. More specifically, the compounds of this invention can be prepared by the

condensation of anthracene-1,9-dicarboxylic anhydride of  
 formula II with an amine of formula  $\text{NH}_2\text{-A-D-NR}_{12}\text{R}_{13}$  (III) as  
 indicated hereinbelow:



In the above equation,  $\text{R}_1, \text{R}_2, \text{R}_3, \text{R}_4, \text{R}_5, \text{R}_6, \text{R}_7, \text{R}_8, \text{R}_9, \text{R}_{10}, \text{R}_{11}, \text{R}_{12}, \text{R}_{13}, \text{A}, \text{D}, \text{n}_1, \text{n}_2$  and  $\text{n}_3$  are as defined hereinabove.


The reaction is carried out in inert solvents which are inert to both reactants and products and will dissolve both reactants, e.g., toluene, benzene, petroleum ether, hexanes, methylene chloride, chloroform, carbon tetrachloride alcohol, e.g., methanol, ethanol, and the like. The reaction can be effected at room temperature up to the reflux temperature of the solvent. The preferred solvent is toluene, and it is preferred that the reaction be run at reflux temperatures at a time sufficient for the condensation to occur, e.g., 2-24 hours.

When  $\text{R}_{10}$  is halogen, the other groups representative of  $\text{R}_{10}$  can be prepared by nucleophilic displacement of said halogen at  $\text{R}_{10}$  by strong nucleophiles such as hydroxide and methoxide.

If there are reactive groups on  $\text{R}_8$  or  $\text{R}_6$ , such as  $\text{NH}_2$ ,  $\text{OH}$ , or  $\text{SR}_1$ , they can be protected by blocking groups known in the art. Many of these blocking groups are described in

"Protective Groups in Organic Synthesis" by T.W. Greene,  
John Wiley and Sons, New York, New York, 1981, the contents  
of which are incorporated herein by reference. For example,  
when  $R_8$  or  $R_6$  is  $NH_2$ , it can be protected by such groups as  
N-formyl, and N-acetyl, and the like.

Alternatively, these reactive groups can be placed on  
the rings after the condensation takes place. The following  
scheme is exemplary:



In this scheme,  $\Lambda$ , D,  $R_{12}$  and  $R_{13}$  are as defined hereinabove.


The anthracene-1,9-dicarboxylic anhydride (II A) is nitrated with nitric acid, which is then condensed with the amine to form the nitrated dibenz-isoquinoline-1,3-dione derivative. The nitrated compound is then reduced by a reducing agent, such as  $H_2/Pd$ , or  $H_2/Pt$  and the like, to form the corresponding amine.

As another example, a compound of Formula I, wherein  $\Lambda$ , D,  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$ ,  $R_7$ ,  $R_8$ ,  $R_9$ ,  $R_{10}$ ,  $R_{11}$ ,  $n_1$ ,  $n_2$  and  $n_3$  are as defined hereinabove and  $R_6$  is  $SO_2NH_2$  can be formed as follows:

A compound of Formula I, wherein  $\Lambda$ , D,  $R_8$ ,  $R_{10}$ ,  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_9$ ,  $R_{11}$ ,  $R_7$ ,  $R_4$ ,  $R_5$ ,  $R_{12}$  and  $R_{13}$  are as defined hereinabove and  $R_6$  is hydrogen, is reacted with chlorosulfonic acid ( $ClSO_3H$ ) followed by simple addition by  $NR_{12}R_{13}$  to form the above said compound.

The anthracene 1,9-dicarboxylic anhydride (II) can also be prepared by art recognized techniques.

An exemplary procedure is indicated hereinbelow:



IV

V




In the above procedure,  $R_{11}$ ,  $R_6$ ,  $R_9$ ,  $R_{10}$ ,  $R_9$ ,  $R_8$ ,  $n_1$  and  $n_2$  are as defined hereinabove.

The anthracene derivative II is prepared by treating an anthracene with oxalyl chloride, followed by oxidation with hydrogen peroxide in accordance with the procedure described by E.D. Bergmann and R. Ikan, J. Org. Chem., 23, 907 (1958).

5-substituted compounds of formula I can also be prepared by synthesis from the corresponding 5-substituted indanones. For example, 5-nitroindanone, treated with sodium borohydride followed by triphenylphosphine dibromide, furnishes 1-bromo-5-nitroindan, which is converted into a Grignard reagent by magnesium in ether. Addition of 2-cyclohexenone and cuprous iodide gives 1-(cyclohexanon-3-yl)-5-nitroindan. Conversion of this product into its hydroxymethylene derivative by ethyl formate and sodium ethoxide, followed by cyclization in the presence of polyphosphoric acid affords 7-nitro-4-oxo-1,2,3,4,8b,11a-hexahydrocyclopentanoanthracene, which gives 3-nitro-1,9-cyclopentanoanthracene on reduction with sodium borohydride followed by treatment with dichlorodicyanobenzoquinone. Oxidation of this product with sodium dichromate, followed by acidification furnishes 5-nitro-1,9-dicarboxylic acid anhydride, which gives the desired 5-nitro compound of formula I on treatment with an amine such as dimethylethylenediamine. The nitro group of this compound can be reduced catalytically to an amine using techniques known to one skilled in the art, such as  $H_2/Pd$  or  $H_2/Pt$ .

This amine can be acetylated using an acetyling reagent, such as acetic anhydride. These transformations are exemplified hereinbelow:



The compounds of the invention containing basic  
nitrogen form salts with acids, both organic and inorganic  
acids. Of particular value are salts with pharmaceutically-  
acceptable acids especially in dosage forms predicated on  
aqueous systems where the enhanced water solubility of the  
salts is most advantageous. Salts formed with  
pharmaceutically unacceptable acids are also useful in the  
isolation and purification of the basic nitrogen-containing  
present new compounds. Salts include those formed with  
hydrochloric, sulfuric, nitric, perchloric, benzenesulfonic,  
toluenesulfonic, phosphoric, acetic, malic, malonic,  
tartaric and similar such acids.

The compounds of the present invention can be  
administered to the host in a variety of forms adapted to  
the chosen route of administration, i.e., orally,  
intravenously, intramuscularly or subcutaneously.

The active compound may be orally administered, for  
example, with an inert diluent or with an assimilable edible  
carrier, or it may be enclosed in hard or soft shell gelatin  
capsules, or it may be compressed into tablets, or it may be  
incorporated directly with the food of the diet. For oral  
therapeutic administration, the active compound may be  
incorporated with excipient and used in the form of  
ingestible tablets, buccal tablets, troches, capsules,  
elixirs, suspensions, syrups, wafers, and the like. Such  
compositions and preparations should contain at least 0.1%  
of active compound. The percentage of the compositions and  
preparations may, of course, be varied and may conveniently

be between about 2 to about 60% of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that a suitable dosage will be obtained. Preferred compositions or preparations according to the present invention are prepared so that an oral dosage unit form contains between about 50 and 300 mg of active compound.

The tablets, troches, pills, capsules and the like may also contain the following: A binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin may be added or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar or both. A syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, the active compound may be incorporated into sustained-release preparations and formulations.

The active compound may also be administered parenterally or intraperitoneally. Solutions of the active compound as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

1 The pharmaceutical forms suitable for injectable use  
include sterile aqueous solutions or dispersions and sterile  
powders for the extemporaneous preparation of sterile  
injectable solutions or dispersions. In all cases the form  
must be sterile and must be fluid to the extent that easy  
5 syringability exists. It may be stable under the conditions  
of manufacture and storage and must be preserved against the  
contaminating action of microorganisms such as bacteria and  
fungi. The carrier can be a solvent or dispersion medium  
containing, for example, water, ethanol, polyol (for  
10 example, glycerol, propylene glycol, and liquid polyethylene  
glycol, and the like), suitable mixtures thereof, and  
vegetable oils. The proper fluidity can be maintained, for  
example, by the use of a coating such as lecithin, by the  
maintenance of the required particle size in the case of  
15 dispersion and by the use of surfactants. The prevention of  
the action of microorganisms can be brought about by various  
antibacterial and antifungal agents, for example, parabens,  
chlorobutanol, phenol, sorbic acid, thimerosal, and the  
like. In many cases, it will be preferable to include  
20 isotonic agents, for example, sugars or sodium chloride.  
Prolonged absorption of the injectable compositions can be  
brought about by the use in the compositions of agents  
delaying absorption, for example, aluminum monostearate and  
gelatin.

25 Sterile injectable solutions are prepared by  
incorporating the active compound in the required amount in  
the appropriate solvent with various of the other  
ingredients enumerated above, as required, followed by  
filtered sterilization. Generally, dispersions are prepared  
30 by incorporating the various sterilized active ingredient  
into a sterile vehicle which contains the basic dispersion

1 medium and the required other ingredients from those  
enumerated above. In the case of sterile powders for the  
preparation of sterile injectable solutions, the preferred  
5 methods of preparation are vacuum drying and the  
freeze-drying technique which yield a powder of the active  
ingredient plus any additional desired ingredient from  
previously sterile-filtered solution thereof.

The following examples further illustrate the  
invention. These examples are provided solely for  
illustrative purposes; thus, the present invention should  
10 not be limited thereto.

15

20

25

30

35

EXAMPLE 11 Preparation of Anthracene-1,9-Dicarboxylic Acid Anhydride

5 A suspension of 6.5 g of anthracene-1,9-dicarboxylic  
acid (E.D. Bergmann and R. Ikan, J. Org. Chem., 23, 907  
(1958)) in 100 ml of acetic anhydride was heated at reflux  
for 3 hours. The mixture was cooled and the orange  
precipitate was collected by filtration, washed with ether  
and dried in air to give 5.1 g (68%) of the title compound.  
10 Recrystallization from dimethylsulfoxide or toluene gave  
orange plates with melting point 289-290°C.

15

20

25

30

35

EXAMPLE 2

1 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz(deh)-  
isoquinoline-1,3-dione (1)

5 A suspension of 248 mg (1 mmol) of  
anthracene-1,9-dicarboxylic acid anhydride in 25 ml of  
toluene was treated with 106 mg (1.2 mmol) of  
N,N-dimethylethylenediamine. The mixture was refluxed for 4  
10 hours. The clear yellow reaction solution was concentrated  
under reduced pressure to an oily residue which was isolated  
on a silica gel column using a mixture of chloroform-methanol  
(9.5-0.5 or 9:1) as a solvent to give 245 mg (77%) of the  
title compound, crystallized from toluene, m.p 126-128°C and  
providing the following analysis.

15 <sup>1</sup>H NMR (d<sub>6</sub>DMSO, TS),  $\delta$  values in ppm.  
2.3 (s, 6, N-CH<sub>3</sub>), 2.4-2.65 (t, 2, N-CH<sub>2</sub>), 4.0-4.25  
(t, 2, CON-CH<sub>2</sub>), 7.55-7.9 (m, 3, protons 5 + 9 + 10), 8.05-8.20  
(d, 1, H-8), 8.3-8.5 (t<<d over d>>, 2, H-4 + H-6), 8.9  
20 (s, 1, H-7), 9.6-9.8 (d, 1, H-11).

25

30

35



EXAMPLE 3

1 2-(2'-(N-pyrrolidino)ethyl)-1,2-dihydro-3H-dibenz(deh)iso-  
quinoline-1,3-dione (8)

5 A suspension of 500 mg (2.02 mmol) of anthracene-1,9-  
dicarboxylic anhydride in 10 ml toluene was treated with 250  
mg (2.20 mmol) of 1-(2-aminoethyl)-pyrrolidine. The mixture  
was refluxed overnight. The clear reaction solution was  
separated from resins by decantation. It was then allowed  
10 to cool to room temperature. The crystalline yellow  
material deposited (640 mg. 92%) was collected and  
recrystallized from hexane-toluene 1:1 to give yellow  
crystals of the title compound having a m.p. of 162-164°C  
and providing the following analysis:

15 <sup>1</sup>H NMR (CDCl<sub>3</sub>, TS),  $\delta$  values in ppm.  
1.65-1.95 (m, 4, -CH<sub>2</sub>-), 2.5-3.0 (m, 6, N-CH<sub>2</sub>), 4.35-4.55  
(t, 2, CON-CH<sub>2</sub>), 7.53-7.9 (m, 3, H-5 + H-9 + H-10), 8.0-8.1  
(d, 1, H-8), 8.23-8.33 (d, 1, H-4), 8.65-8.75 (s over d, 2, H-6 +  
20 H-7), 9.9-10.0 (d, 1, H-11).

25

30

35

EXAMPLE 4

1 2-[2'-(N-piperidino)ethyl]-1,2-dihydro-3H-dibenz(deh)iso-  
5 quinoline-1,3-dione (7)

10 A suspension of 500 mg (2.02 mmol) of anthracene-1,9-  
dicarboxylic anhydride in 10 ml toluene was treated with 283  
mg (2.21 mmol) of 1-(2-aminoethyl)piperidine. The mixture  
was refluxed overnight under nitrogen. The clear reaction  
solution was separated from tarry material by decantation.  
It was then allowed to cool to room temperature. The dark  
yellow solid that precipitated (715 mg, 99%) was collected  
and crystallized from a mixture of hexane-toluene 1:1,  
affording yellow crystals of m.p. 171-173°C and providing  
the following analysis:

15 <sup>1</sup>H NMR (CDCl<sub>3</sub>, TS), δ values in ppm.  
1.1-1.8 (m, 6, -CH<sub>2</sub>-), 2.5-2.9 (m, 6, N-CH<sub>2</sub>), 4.35-4.55  
(t, 2, CON-CH<sub>2</sub>), 7.55-7.90 (m, 3, H-5 + H-9 + H-10), 8.05-8.15  
(d, 1, H-8), 8.25-8.35 (d, 1, H-4), 8.65-8.75 (s over d, 2,  
20 H-6 + H-7), 9.9-10.0 (d, 2, H-11).

25

30

35

EXAMPLE 5

1 2-(1'-ethyl-3'piperidinyl)-1,2-dihydro-3H-dibenz(deh)-  
isoquinoline-1,3-dione (9)

5 A suspension of 600 mg (2.42 mmol) of  
anthracene-1,9-dicarboxylic acid anhydride in 10 ml toluene  
was treated with 343 mg (2.68 mmol) of 3-amino-1-ethyl  
piperidine. The mixture was refluxed under nitrogen  
overnight. The clear reaction solution was separated from  
10 tarry material by decantation. The toluene was evaporated  
to give 800 mg (92%) of light brown solid, which was  
crystallized from a mixture of hexane-toluene (2:1) as buff  
crystals of the title compound, having melting point  
163-165°C and providing the following analysis:

15 <sup>1</sup>H NMR (CDCl<sub>3</sub>, TS), δ values in ppm  
1.05-1.20 (t, 3, CH<sub>3</sub>), 1.3-2.2 (m, 4, -CH<sub>2</sub>-), 2.25-2.75  
(m, 4, N-CH<sub>2</sub> endocyclic), 2.9-3.1 (m, 2, N-CH<sub>2</sub> exocyclic),  
5.2-5.62 (m, 1, CON-CH), 7.5-7.9 (m, 3, H-5 + H-9 + H-10),  
20 8.0-8.10 (d, 1, H-8), 8.25-8.35 (d, 1, H-4), 8.65-8.75 (s over  
d, 2, H-6 + H-7), 9.85-9.95 (d, 1, H-11).

25

30

35

EXAMPLE 6

1 2-[3'-(Diethanolamino)aminopropyl]-1,2-dihydro-3H-dibenz  
(deh)isoquinoline-1,3-dione (12)

5 A suspension of 248 mg (1 mmol) of  
anthracene-1,9-dicarboxylic anhydride in 45 ml of dry  
toluene was treated with 194 mg (1.2 mmole) of  
N-(3-aminopropyl)diethanolamine in 1 ml of absolute ethanol.  
The mixture was refluxed under nitrogen for 7 hours. The  
10 solvent was evaporated and the residue was isolated on a  
silica gel column using a mixture of chloroform-methanol  
(8:2) as a solvent to give 311 mg (79%) of the title  
compound which was crystallized from toluene into yellow  
needles of melting point 139-141°C and providing the  
15 following analysis:

$H^1$  NMR ( $CDCl_3$ , TS),  $\delta$  values in ppm  
1.8-2.1 (quintuplet, 2,  $-CH_2-$ ), 2.65-2.8 (m, 6,  $N-CH_2$ ),  
3.68-3.78 (t, 4,  $CH_2-OH$ ), 3.0-3.3 (br, 2, OH), 4.2-4.4  
20 (t, 2,  $CON-CH_2$ ), 7.5-7.85 (m, 3,  $H-5 + H-9 + H-10$ ), 7.95-8.05  
(d, 1,  $H-8$ ), 8.15-8.25 (d, 1,  $H-4$ ), 8.6-8.7 (s over d, 2,  $H-6 +$   
 $H-7$ ), 9.75-9.85 (d, 1,  $H-11$ ).

25

30

35

EXAMPLE 7

1 2-[3'-(dimethylamino)propyl]-1,2-dihydro-3H-dibenz(deh)-  
isoquinoline-1,3-dione (11)

5 A suspension of 600 mg (2.42 mmol) of anthracene-1,9-  
dicarboxylic anhydride in 15 ml toluene was treated with 280  
mg (2.75 mmol) of 3-dimethylaminopropylamine. The mixture  
was refluxed under nitrogen overnight. The clear solution  
was separated from tarry material by decantation.  
10 Evaporation of the solvent gave 715 mg (89%) of the title  
compound which crystallized from a mixture of hexane-  
toluene (2:1) as yellow needles of melting point 111-113°C  
and providing the following analysis:

15 <sup>1</sup>H NMR (CDCl<sub>3</sub>, TS), δ values in ppm  
1.9-2.15 (quintuplet, 2, -CH<sub>2</sub>-), 2.3 (s, 6, N-CH<sub>3</sub>), 2.4-2.6  
(t, 2, N-CH<sub>2</sub>), 4.2-4.4 (t, 2, CON-CH<sub>2</sub>), 7.48-7.85 (m, 3, H-5 + H-9  
+ H-10), 7.95-8.05 (d, 1, H-8), 8.2-8.3 (d, 1, H-4), 8.60-8.70  
(s over d, 2, H-6 + H-7), 9.85-9.995 (d, 1, H-11).

20

25

30

35

EXAMPLE 8

1 2-(4'-dimethylaminophenyl)-1,2-dihydro-3H-dibenz(deh)-  
isoquinoline-1,3-dione (10)

5 A suspension of 300 mg (1.21 mmole) of anthracene-1,9-  
dicarboxylic anhydride in 40 ml of absolute ethanol was  
treated with a solution of 494 mg (3.63 mmole) of  
N,N-dimethyl-p-phenylenediamine in 10 ml of absolute  
ethanol. After refluxing the mixture under nitrogen for 24  
10 hours, 20 ml of dry toluene was added and the mixture was  
refluxed for another 72 hours. The insoluble yellow solid  
(340 mg) was filtered off and dried in air. It was boiled  
with 100 ml of dioxane and the insoluble material (110 mg)  
which represents unreacted anhydride was filtered off. The  
15 filtrate, upon evaporation, gave 230 mg (82% based on  
reacted amount) of the title compound which was crystallized  
from dioxane into yellow needles having a melting point of  
332-334°C and providing the following analysis:

20 <sup>1</sup>H NMR (d<sub>6</sub>DMSO, TS), δ values in ppm.

3.18 (s, 6, N-CH<sub>3</sub>), 7.37-7.43 (t, 1, H-9), 7.47-7.61 (m, 4, H-5 + H-10 + H-3' + H-5'), 7.69-7.72 (d, 2, H-2' +  
H-6'), 7.89-7.92 (d, 1, H-8), 8.18-8.22 (d, 1, H-4), 8.41-8.44  
25 (d, 1, H-6), 8.65 (s, 1, H-7), 9.50-9.56 (d, 1, H-11).

30

35

EXAMPLE 9

1 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-8-nitro-3H-dibenz-  
(deh)isoquinoline-1,3-dione (13) and 2-[2-(dimethylamino)-  
ethyl]-1,2-dihydro-11-nitro-2H-dibenz(deh)isoquinoline-1,3-  
5 dione (2)

A stirred solution of 416 mg (1.68 mmol) of  
anthracene-1,9-dicarboxylic acid anhydride in 25 ml of  
concentrated sulfuric acid was treated at -10 to -12°C with  
10 a solution of 155 mg of 70% nitric acid (1.7 mmol) in 1 ml  
of concentrated sulfuric acid. Stirring was continued for  
15 minutes after the addition was complete and then the  
mixture was poured over ice water. The resulting yellow  
precipitate, a mixture of isomeric mononitro derivatives,  
was washed well with water and dried in air. It was used  
15 directly in the next step.

A suspension of 570 mg (1.95 mmol) of a mixture of  
mononitro derivatives in 50 ml of dry toluene was treated  
with a solution of 206 mg (2.35 mmol) of  
20 N,N-dimethylethylenediamine in 15 ml of dry ethanol. The  
mixture was heated at reflux for 4 hours, during which time  
a clear brownish yellow solution formed. After evaporation  
of the solvent, the solid residue was separated into its  
components by chromatography on a silica gel column using  
chloroform-acetone (1:1) as solvent. Concentration of the  
25 first yellow fraction gave 247 mg (35%) of 2-[2'-(dimethyl-  
amino)ethyl]-1,2-dihydro-11-nitro-3H-dibenz(deh)isoquinoline-  
1,3-dione, which was crystallized from toluene to give  
yellow flakes with melting point 238-240°C and providing the  
30 following analysis:

<sup>1</sup>H NMR (d<sub>6</sub>DMSO, TS), δ values in ppm.

1 2.99 (s, 6, NCH<sub>3</sub>), 3.52-3.57 (t, 2, NCH<sub>2</sub>), 4.49-4.53  
(t, 2, CONCH<sub>2</sub>), 7.79-7.86 (t, 1, H-5), 7.92-7.98 (t, 1, H-9),  
5 8.47-8.50 (d, 1, H-4), 8.59-8.67 [doublet over doublet  
(appears as triplet), 2, H-6 + H-8], 8.75-8.77 (d, 1, H-10),  
9.32 (s, 1, H-7).

10 Concentration of the second yellow fraction gave 181 mg  
(26%) of 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-8-nitro-3H-  
dibenz(deh)isoquinoline-1,3-dione, which was crystallized  
from hexane-toluene (1:1) into brownish-yellow cubes with  
melting point 210-212°C and providing the following  
analysis:

15 <sup>1</sup>H NMR (CDCl<sub>3</sub>, TS), δ values in ppm.

2.40 (s, 6, NCH<sub>3</sub>), 2.70-2.77 (t, 2, NCH<sub>2</sub>), 4.39-4.45  
(t, 2, CON-CH<sub>2</sub>), 7.77-7.86 (m, 2, H-5 + H-10), 8.27-8.30  
(d, 1, H-4), 8.35-8.39 (d, 1, H-6), 8.75-8.80 (d, 1, H-9), 9.42  
20 (s, 1, H-7), 10.34-10.38 (d, 1, H-11).

25

30

35



EXAMPLE 10

1 8-Amino-2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz-  
(deh)isoquinoline-1,3-dione (14)

5 A solution of 84 mg of 2-[2'-(dimethylamino)ethyl]-8-nitro-1,2-dihydro-3H-dibenz-(deh)isoquinoline-1,3-dione in  
10 100 ml of absolute ethanol was treated with 10 mg of palladium-on-carbon catalyst and shaken with hydrogen at 42 p.s.i. for 5 hours. The mixture was filtered and the  
filtrate was evaporated to give 77 mg (99.9%) of the title  
compound as a brown solid that melted partially at 165-168°C  
and completely at 200-202°C (melting point of the  
dihydrochloride salt was above 300°C).

15

20

25

30

35

EXAMPLE 11

1 2-[2'-(dimethylamino)ethyl]1,2-dihydro-6-ethyl-3H-dibenz-  
(deh)isoquinoline-1,3-dione (15)

5 A solution of 500 mg of 2-[2'-(dimethylamino)ethyl]-1,2-  
dihydro-3H-dibenz(deh)isoquinoline-1,3-dione in 30 ml of dry  
tetrahydrofuran was treated with 4 ml of a 2M solution of  
ethyl magnesium bromide in tetrahydrofuran. The mixture was  
10 stirred overnight and then poured into saturated ammonium  
chloride solution. The two layers were separated and the  
aqueous layer was extracted with chloroform. The combined  
organic layers were dried over sodium sulfate and then  
15 evaporated to give an oily residue that was separated into  
its components by preparative thin-layer chromatography on  
silica gel with acetone-toluene (2:8) as solvent to give  
starting material (94 mg), a polar brown oil containing 3  
components (268 mg), and the title compound (least polar)  
(118 mg, 27% based on converted starting material) as a  
yellow solid. The title compound gave upon  
20 recrystallization from hexane-toluene (3:1) yellow needles  
having a melting point of 148-150°C and providing the  
following analysis:

<sup>1</sup>H NMR (CDCl<sub>3</sub>, TS), 6 values in ppm

25 1.37-1.43 (t, 3, CH<sub>3</sub>), 2.42 (s, 6, N-CH<sub>3</sub>), 2.69-2.75  
(t, 2, N-CH<sub>2</sub>), 3.44-3.53 (q, 2, CH<sub>2</sub>), 4.39-4.44 (t, 2, CON-CH<sub>2</sub>),  
7.46-7.49 (d, 1, H-5), 7.53-7.59 (t, 1, H-9), 7.72-7.79  
(t, 1, H-10), 7.98-8.02 (d, 1, H-8), 8.10-8.13 (d, 1, H-4), 8.61  
30 (s, 1, H-7), 9.93-9.97 (d, 1, H-11).

35

EXAMPLE 12

1 11-Amino-2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz-  
(deh)isoquinoline-1,3-dione (3)

5 A solution of 100 mg of 2-[2'-(dimethylamino)ethyl]-11-nitro-1,2-dihydro-3H-dibenz(deh)isoquinoline-1,3-dione in 100 ml of absolute ethanol was treated with 12 mg of palladium-on-carbon and shaken with hydrogen at 42 p.s.i. for 5 hours. The mixture was filtered and the filtrate was  
10 concentrated to give 91 mg (99%) of the title compound as a brown solid having a melting point of 150-152°C (melting point of dihydrochloride salt was above 300°C) and providing the following analysis:

15 <sup>1</sup>H NMR (d<sub>6</sub>DMSO, TS), δ values in ppm.  
2.94 (s, 6, N-CH<sub>3</sub>), 3.30-3.60 (broad, 2, NH<sub>2</sub>), 3.63-3.70 (t, 2, N-CH<sub>2</sub>), 4.50-4.54 (t, 2, CON-CH<sub>2</sub>), 7.81-7.87 (t, 1, H-9), 7.93-8.02 (q<<d over t>>, 2, H-5 + H-10), 8.37-8.41 (d, 1, H-8), 8.68-8.75 (t<<d over d>>, 2, H-4 + H-6), 9.41 (s, 1, H-7).

20

25

30

35

Example 13Preparation of 7-Chloroanthracene-1,9-Dicarboxylic Acid Anhydride

A suspension of 2.0 g of 7-chloro-1,9-oxalyanthracene [Liebermann and Butescu, Chem. Ber., 45, 1213 (1912)] in 40 ml of p-dioxan was treated with 15 ml of 2N NaOH solution and 12 ml of 30% hydrogen peroxide. The ensuing exothermic reaction was controlled by cooling in an ice-water bath. After 40 minutes standing at room temperature, the resulting solution was acidified with dilute  $H_2SO_4$  and the yellow precipitate that formed was collected by filtration, washed with water, and dried in air to give 2.14 g (95%) of the dicarboxylic acid. After recrystallization from p-dioxan and dimethylsulfoxide (4:1), it melted at 325-327°C (anhydride formed on heating).

A suspension of 2.0 g of the dicarboxylic acid in 50 ml of acetic anhydride was heated under reflux for 48 hours and then cooled to room temperature. The resulting orange solid, after being washed with ethanol and dried, afforded 1.84 g (97%) of the title compound. Recrystallization from p-dioxan and dimethylsulfoxide (4:1) gave orange crystals with melting point 325-327°C.

Example 14

1 10-Chloro-2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz-  
(dch)isoquinoline-1,3-dione (16)

5 A mixture of 1 g (3.6 mmol) of 7-chloroanthracene-1,9-  
dicarboxylic acid anhydride and 0.36 g (4 mmol) of  
N,N-dimethylethylenediamine in 70 ml of dry toluene was  
heated under reflux for 8 hours. The resulting solution was  
evaporated under reduced pressure and the orange residue was  
10 purified by column chromatography on silica gel with  
toluene-methanol (9:1) as solvent. This procedure gave 1.23  
g (99%) of the title compound, crystallized from toluene,  
m.p. 165-167°C and providing the following analysis.

15 <sup>1</sup>H NMR (d<sub>6</sub>DMSO, TS), 6 values in ppm.

2.4(s, 6, N-CH<sub>3</sub>), 2.56-2.80 (t, 2, N-CH<sub>2</sub>),  
4.3-4.46(t, 2, CON-CH<sub>2</sub>), 7.45-7.60 (t, 1, H-5),  
7.68-7.78 (d, 1, H-9), 7.87-7.97 (d, 1, H-8), 8.19-8.29  
20 (d, 1, H-4), 8.62 (s over d, 1, H-7),  
8.62-8.72 (d over s, 1, H-6), 9.93 (s, 1, H-11).

25

30

35

Example 15Preparation of 10-Chloroanthracene-1,9-Dicarboxylic Acid Anhydride

To a cold (0°C) stirred mixture of 5.0 g (23.5 mmol) of 9-Chloroanthracene and 6.5 ml of oxalyl chloride in 35 ml of carbon disulfide was added 4 g of anhydrous aluminum chloride. After two hours additional carbon disulfide (15 ml) and aluminum chloride (4 g) were added. The mixture was stirred 2 more hours at 0°C and then overnight at room temperature. Dilute HCl was added and the orange precipitate that formed was collected by filtration, washed with water, and then digested well with 100 ml of 5% NaOH solution. The insoluble solids were collected, washed with water and dried in air to give 4.16 g (66%) of 10-chloro-1,9-oxalyl-anthracene, m.p. 255-258°C, after crystallation from methanol containing a little p-dioxan. Acidification of the filtrate gave 1.83 g of 10-chloro-9-anthroic acid.

A suspension of 2 g (7.5 mmol) of 10-chloro-1,9-oxalylanthracene in 14 ml of 2N NaOH and 120 ml of p-dioxan at 15°C was treated portionwise with 14 ml of 30% hydrogen peroxide solution with shaking. After this addition was complete, the mixture was stirred at room temperature for 1 hour, and then diluted with 100 ml of water. Acidification with dilute H<sub>2</sub>SO<sub>4</sub> resulted in the precipitation of 1.95 g (86%), after drying in air, of 10-chloroanthracene-1,9-dicarboxylic acid. It had a melting point 269-271°C (anhydride formed on heating) after crystallization from p-dioxan.

A suspension of 1.45 g (4.8 mmol) of 10-chloranthracene-1,9-dicarboxylic acid in 50 ml of acetic anhydride was heated under reflux for 4 hours and then cooled to room temperature. The yellow precipitate that formed was collected by filtration, washed with cold methanol and dried to give 0.83 g (61%) of the title compound, m.p. 269-271°C.

Example 16

1 7-Chloro-2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz-  
(deh)-isoquinoline-1,3-dione (17)

5 A mixture of 0.823 g (2.9 mmol) of 10-chloroanthracene-  
1,9-dicarboxylic acid anhydride and 0.256 g (3.0 mmol) of  
N,N-dimethylethylenediamine in 50 ml of dry toluene was  
heated under reflux for 48 hours. The resulting solution  
was evaporated to dryness and the residue was purified by  
10 column chromatography on silica gel with toluene-methanol  
(8:2) as solvent, affording a yellow solid that was purified  
further by preparative thin-layer chromatography on silica  
gel with toluene-methanol (9:1) as solvent. This procedure  
gave 0.71 g (69%) of the title compound, which had m.p.  
15 169-171°C (decomposition) after recrystallization from  
hexane and toluene (4:1) and providing the following  
analysis.

<sup>1</sup>H NMR (CDCl<sub>3</sub>, TS), δ values in ppm.  
20 2.4(s, 6, N-CH<sub>3</sub>), 2.65-2.78(t, 2, N-CH<sub>2</sub>), 4.3-4.46(t, 2, CON-CH<sub>2</sub>),  
7.5-7.82 (m, 3, H-5 + H-9 + H-10), 8.44-8.54 (d, 1, H-8),  
8.65-8.7 (d, 2, H-4 + H-6), 9.88-9.98(d, 1, H-11).

25

30

35

Example 17

1 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-7-hydroxy-3H-dibenz-  
(dch)isoquinoline-1,3-dione (21)

5 A solution of 50 mg (0.14 mmol) of 7-chloro-2-[2'-  
(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz(deh)-isoquinoline-  
1,3-dione in 50 ml of methanol was treated with a solution  
of 12 mg (0.3 mmol) of NaOH in 1.5 ml of water. The mixture  
was stirred for 6 hours, treated with a few drops of glacial  
10 acetic acid, and evaporated to dryness. The residue was  
purified by preparative thin-layer chromatography on silica  
gel with toluene-methanol (9:1) as solvent to give 30 mg  
(63%) of the title compound, crystallized from  
hexane-toluene (1:1) containing a little methanol, as orange  
15 crystals with melting point 163-165°C and providing the  
following analysis.

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , TS),  $\delta$  values in ppm.

20 2.4(s, 6, N- $\text{CH}_3$ ), 2.70-2.73(t, 2, N- $\text{CH}_2$ ), 4.23(s, 1,  
OH), 4.40-4.43(t, 2, CON- $\text{CH}_2$ ), 7.62-7.65 (t, 1, H-5),  
7.71-7.74(t, 1, H-9), 7.80-7.83(t, 1, H-10), 8.40-8.44(d, 1, H-8),  
8.64-8.65 (d, 1, H-4), 8.74-8.76 (d, 1, H-6), 10.03-10.05  
(d, 1, H-10).

IR (KBr disk)  $3440\text{ cm}^{-1}$  (OH).



Example 18

1 2-[2'-(Dimethylamino)ethyl]-1,2-dihydro-7-methoxy-3H-dibenz-  
(deh)isoquinoline-1,3-dione (20)

5 A solution of 50 mg (0.14 mmol) of 7-chloro-2-[2'-  
(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz(deh)-isoquinoline-  
1,3-dione in 25 ml of dry methanol was treated with a  
solution of 16.2 mg (0.30 mmol) of sodium methoxide in 2 ml  
of dry methanol. The mixture was stirred for 24 hours,  
10 treated with a few drops of glacial acetic acid, and  
concentrated under reduced pressure. The concentrate was  
purified by preparative thin-layer chromatography on silica  
gel with toluene-methanol (9:1) as solvent to give 43 mg  
(87%) of the title compound, crystallized from  
15 hexane-toluene (5:1) as red needles with melting point  
147-149°C and providing the following analysis.

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , TS),  $\delta$  values in ppm.  
2.4(s, 6, N- $\text{CH}_3$ ), 2.65-2.8(t, 2, N- $\text{CH}_2$ ), 4.23(s, 3,  
20 OCH<sub>3</sub>), 4.33-4.48(t, 2, CON- $\text{CH}_2$ ), 7.52-7.88 (m, 3, H-5 + H-9 +  
H-10), 8.37-8.47(d, 1, H-8), 8.58-8.78 (t<<d over d>>, 2, H-4  
+ H-6), 9.95-10.06 (d, 1, H-11).

25

30

35

Example 19

1 Preparation of 10-methylanthracene-1,9-Dicarboxylic Acid  
Anhydride

5 To a cold (0°C) stirred mixture of 5 g (26 mmol) of  
9-methylanthracene and 6.5 ml of oxalyl chloride in 35 ml of  
carbon disulfide was added 4 g of anhydrous aluminum  
chloride. After two hours another 4 g of anhydrous aluminum  
10 chloride and 35 ml of carbon disulfide were added and  
stirring at 0°C was continued for two hours. The mixture  
was kept at room temperature overnight, treated with dilute  
HCl, and the orange precipitate that formed was collected by  
filtration, washed with water and then digested well with  
15 100 ml of 5% NaOH solution. The insoluble solids were  
collected by filtration, washed with water and dried to give  
3.17 g (50%) of 10-methyl-1,9-oxalyanthracene, m.p.  
266-268°C, after crystallation from p-dioxan. Acidification  
of the filtrate with concentrated HCl gave 2.06 g of  
10-methyl-9-anthroic acid.

20 A cold (10°C) suspension of 2.0 g (8.12 mmol) of  
10-methyl-1,9-oxalyanthracene in 80 ml of p-dioxan and 15  
ml of 2N NaOH was treated portionwise with 13 ml of 30%  
hydrogen peroxide with shaking. An exothermic reaction  
ensued and the solids dissolved gradually. After the  
25 addition was complete, the mixture was stirred for 40  
minutes, and then acidified with dilute H<sub>2</sub>SO<sub>4</sub>. The  
resulting orange precipitate was collected by filtration,  
washed with water and dried to give 1.97 g (87%) of  
10-methyl-1,9-anthracene dicarboxylic acid, which formed  
30 yellow crystals, m.p. 275-280°C (anhydride formed on  
heating) after recrystallization from chloroform-p-dioxan  
(2:1).

35 A suspension of 1.82 g (6.5 mmol) of the dicarboxylic  
acid in 25 ml of acetic anhydride was heated under reflux  
for 4 hours and then cooled to room temperature. The yellow  
solid was washed with ether and dried to afford 1.04

g of the title compound, m.p. 275-280°C. A further 0.27 g  
1 (total yield 77%) of this compound was obtained by  
evaporating the filtrate and digesting the residue twice  
with n-hexane.

5

10

15

20

25

30

35

Example 20

1 2-[2'-(Dimethylamino)ethyl]-1,2-dihydro-7-methyl-3H-dibenz-  
(dch)isoquinoline-1,3-dione (19)

5 A mixture of 500 mg (1.91 mmol) of 10-methylanthracene-  
1,9-dicarboxylic acid anhydride and 2.0 mmol N,N-dimethyl-  
ethylenediamine in 50 ml of dry toluene was heated under  
reflux for 5 hours. The solvent was evaporated and the  
10 residual solid was purified by column chromatography on  
silica gel with chloroform-methanol (9:1) as solvent. This  
procedure gave 605 mg (95%) of the title compound,  
crystallized from hexane-toluene (3:1), golden needles with  
m.p. 155-157°C and providing the following analysis.

15 <sup>1</sup>H NMR (CDCl<sub>3</sub>, TS), δ values in ppm  
2.4(s, 6, N-CH<sub>3</sub>), 2.63-2.80(t, 2, NCH<sub>2</sub>), 3.08(s, 3,  
CH<sub>3</sub>), 4.29-4.46(t, 2, CON-CH<sub>2</sub>), 7.47-7.82 (m, 3, H-5 + H-9 +  
H-10), 8.20-8.30(d, 1, H-8), 8.48-8.58 (d, 1, H-4),  
8.59-8.69(d, 1, H-6), 9.90-10.00(d, 1, H-11).

20

25

30

35

Example 21

1 1,2-Dihydro-2-[2'-(methylamino)ethyl]-3H-dibenz(deh)-  
2 isoquinoline-1,3-dione (22)

5 A mixture of 477 mg (1.5 mmol) of 2-[2'-(dimethylamino)  
ethyl]-1,2-dihydro-3H-dibenz(deh)isoquinoline-1,3-dione, 240  
mg (1.5 mmol) of bromine, and 25 ml of glacial acetic acid  
was heated under reflux for 24 hours, cooled to room  
10 temperature, and diluted with ether. The solid that  
separated was dissolved in methanol and this solution was  
treated with methanolic KOH until it became slightly  
alkaline. It was then concentrated and the residue was  
15 separated into its components by column chromatography on  
silica gel with chloroform-methanol (19:1, then 9:1) as  
solvent. The first fraction (orange) gave 400 mg of  
unreacted starting material. The second fraction (green)  
gave a solid that was purified by preparative TLC on silica  
gel with chloroform-methanol (9:1) as solvent. This  
20 procedure gave 39 mg of the title compound, which formed a  
hydrochloride salt of m.p. 230-235°C (decomposition). The  
title compound provided the following analysis.

25 <sup>1</sup>H NMR (CDCl<sub>3</sub>, TS), δ values in ppm.  
1.22(s, 1, HN), 2.55(s, 3, NCH<sub>3</sub>), 3.06-3.11(t, 2, NCH<sub>2</sub>,  
4.39-4.44(t, 2, CON-CH<sub>2</sub>), 7.52-7.66 (m, 2, H-5 + H-9),  
7.72-7.79(t, 1, H-10), 7.98-8.01(d, 1, H-8), 8.21-8.24(d, 1, H-4),  
8.62-8.65(d, 1, H-6), 8.66(s, 1, H-7), 9.84-9.88(d, 1, H-11).

30

35

Example 22

1 1,2-dihydro-2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz-  
2 (deh)-isoquinoline-1,3-dione-8-sulfonamide

5 The product of Example 1 is reacted with chlorosulfonic  
6 acid, followed by ammonia, and then dimethylethylenediamine  
7 in accordance with the procedure described in Example 2, to  
8 form the above-identified product.

10

15

20

25

30

35

Example 23

1 Preparation of a Mixture of 2-, 6-, and 7-Acetamidoanthracene-  
1,9-dicarboxylic Acids

5 2-Acetamidoanthracene was prepared in 97% yield by  
stirring a solution of 1 equivalent of 2-aminoanthracene and  
1.5 equivalents of acetic anhydride in dry tetrahydrofuran  
for 3 hours at room temperature. This product (2.9 g) was  
dissolved in 35 ml of carbon disulfide and 4 ml of oxalyl  
10 chloride was added. The stirred mixture was cooled to 0°C  
and treated with 2.5 g of anhydrous aluminum chloride.  
Another 35 ml of carbon disulfide and 2.5 g of aluminum  
chloride were added after 2 hours. The mixture was stirred  
2 hours at 0°C and overnight at room temperature and then  
15 treated with dilute HCl. The brown precipitate that formed  
was washed with water and then digested well with 5% NaOH  
solution. After collection, the insoluble solids were  
washed with water and dried in air to give 1.25 g (35%) of a  
mixture of 2-, 6-, and 7-acetamido-1,9-oxalyanthracenes.

20 A suspension of the acetamidooxalyanthracenes (1.24 g,  
4.27 mmol) in 25 ml of p-dioxane and 8 ml of 5% NaOH was  
treated at 15°C with 8 ml of 30% hydrogen peroxide. The  
mixture was stirred 45 minutes at room temperature, diluted  
with 50 ml of water, and filtered. The clear brown filtrate  
25 was acidified with dilute H<sub>2</sub>SO<sub>4</sub> and the brick-red solid that  
formed was collected, washed well with water and dried in  
air to give 1.1 g (80%) of a mixture of the title compounds.  
This mixture was used directly in Example 24.

30

35

Example 24

1 4-, 9-, and 10-Acetamido-2-[2'-(dimethylamino)ethyl]-1,2-  
dihydro-3H-dibenz(deh)isoquinoline-1,3-diones

5 A suspension of a mixture of 2-,3-,6-, and 7-acetamido-  
1,9-dicarboxylic acids (1 g, 3.09 mmol) in 50 ml of dry  
toluene was heated under reflux with 310 mg (3.52 mmol) of  
N,N-dimethylethylenediamine for 15 hours. Anhydrous ethanol  
(10 ml) was added and reflux was continued another 5 hours.  
10 The mixture was concentrated under reduced pressure and the  
oily residue was chromatographed on silica gel with  
toluene-methanol as solvent. (8:2). Three fractions were  
obtained. The first fraction was purified further by  
preparative TLC on silica gel to give 27 mg (2%) of  
15 4-acetamido-2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-  
dibenz(deh)-isoquinoline-1,3-dione as yellow solid. The  
second fraction gave 244 mg. of another isomeric acetamido  
derivative, melting point 249-252°C. An orange solid (714  
mg) obtained from the third fraction was extracted with  
20 chloroform. The insoluble solid was washed with chloroform  
and dried in air to give 79 mg (7%) of 10-acetamido-2-[2'-  
(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz(deh)-  
isoquinoline-1,3-dione, which did not melt below 360°C.  
Concentration of the chloroform extract gave 632 mg (55%) of  
25 9-acetamido-2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibe-  
nz(deh)isoquinoline-1,3-dione, melting point 197-199°C after  
crystallization from toluene.

30

35



Example 25

1 9-Amino-2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz(deh)  
isoquinoline-1,3-dione

5 A mixture of 210.3 mg of 9-acetamido-2-[2'-(di-  
methylamino)ethyl]-1,2-dihydro-3H-dibenz(deh)isoquinoline-1,  
3-dione, 50 ml of ethanol, and 5 ml of 37% HCl was heated  
under reflux for 2 hours and then concentrated to dryness.  
The residue was dissolved in methanol and this solution was  
10 made alkaline with methanolic KOH. It was then concentrated  
to a residue that was purified by preparative TLC on silica  
gel with toluene-methanol (9:1) as solvent. This procedure  
gave 162 mg (76%) of the title compound as a brick-red solid  
that had melting point 193-145°C after crystallization from  
15 toluene.

20

25

30

35

Example 26

1 10-Amino-2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz-  
(deh)isoquinoline-1,3-dione

5 The title compound was prepared by the procedure of  
Example 25. From 54 mg of 10-Acetamidomino-2-[2'-(di-  
methylamino)ethyl]-1,2-dihydro-3H-dibenz(deh)isoquinoline-1,  
3-dione was obtained 5 mg (10%) of the title compound.

10

15

20

25

30

35

Example 27

1 4-Amino-2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz-  
(deh)isoquinoline-1,3-dione

5 The title compound was prepared by the procedure of  
Example 25. From 15 mg of 4-acetamido-2-[2'-(dimethylamino)  
ethyl]-1,2-dihydro-3H-dibenz(deh)isoquinoline-1,3-dione was  
obtained 7 mg (53%) of the title compound.

10

15

20

25

30

35

Example 28

1 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-7-methylthio-3H-di-  
benz(deh)isoquinoline-1,3-dione

5 A solution of 50 mg (0.142 mmol) of 2-[2'-(dimethylamino)  
ethyl]-1,2-dihydro-7-chloro-3H-dibenz(deh)isoquinoline-1,  
3-dione in 30 ml of warm anhydrous methanol was treated with  
12 mg (0.17 mmol) of sodium thiomethoxide. The mixture was  
10 stirred overnight at room temperature and concentrated to  
dryness. The residue was purified by preparative TLC on  
silica gel with toluene-methanol (9:1) as solvent to give 34  
mg (66%) of the title compound, having a melting point of  
137-139°C and providing the following analysis:

15 <sup>1</sup>H NMR (CDCl<sub>3</sub>, TS), δ values in ppm.

2.35(s,6,N-CH<sub>3</sub>), 2.40(s,3,S-CH<sub>3</sub>), 2.58-2.75(t,2,N-CH<sub>2</sub>),  
4.27-4.42(t,2,CONH<sub>2</sub>), 7.53-7.83(m,3,H-5 + H-9 + H-10),  
8.65-8.73(d,1,H-8), 8.96-9.06(d,1,H-4), 9.18-9.28(d,1,H-6),  
20 9.90-10.00(d,1,H-11).

25

30

35

Example 29

1 2-(2'-Imidazoliny1)methyl]-1,2-dihydro-3H-dibenz(dch)iso-  
quinolin-1,3-dione

5 By treating the compound prepared in Example 1 with  
amino acetonitrile followed by ethylene diamine dihydro-  
chloride in accordance with the procedure described in  
Example 2, the above-identified compound can be prepared.

10

15

20

25

30

35

Example 30

1       Using Anthracene-1,9-Dicarboxylic Acid anhydride  
prepared in Example 1 and the appropriate amine, the  
following compounds can be prepared in accordance with the  
5       procedure described in Example 2:

2-[2'-(1-piperazinyl)ethyl]-1,2-dihydro-3H-dibenz(deh)isoquin-  
oline-1, 3-dione;

2-[2'-(N-morpholinyl)ethyl]-1,2-dihydro-3H-dibenz(deh)-  
10       isoquinoline-1, 3-dione;

2-[(1'-ethyl-2-pyrrolidinyl)methyl]-1,2-dihydro-3H-dibenz-  
(deh)isoquinoline-1, 3-dione;

2-[2'-(1-methyl)-2-pyrrolidinyl)ethyl]-1,2-dihydro-3H-dibenz-  
(deh)isoquinoline-1, 3-dione;

15       2-[(3'-piperidinyl)methyl]-1,2-dihydro-3H-dibenz(deh)-  
isoquinoline-1, 3-dione;

2-(3'-pyridyl)-1,2-dihydro-3H-dibenz(deh)isoquinoline-  
1,3-dione;

2-[2'-(2-pyridyl)ethyl]-1,2-dihydro-3H-dibenz(deh)-  
20       isoquinoline-1, 3-dione;

2-[(1'-aziridinyl)ethyl]-1,2-dihydro-3H-dibenz(deh)-  
isoquinoline-1, 3-dione.

25

30

35

Example 31

1           Similarly, using the procedure described herein, the  
following derivatives of 2-(2'-(dimethylaminoethyl)-1,2-  
dihydro-3H-dibenz(deh)isoquinoline-1,3-dione can be  
5       prepared:

4-OH, OCH<sub>3</sub>, NO<sub>2</sub>, Cl, Br or CF<sub>3</sub>;  
5-OH, or OCH<sub>3</sub>, Cl, or Br;  
6-NHCOCH<sub>3</sub>, NH<sub>2</sub>, OH, OCH<sub>3</sub>, Cl, Br, CF<sub>3</sub>, NO<sub>2</sub>, or CH<sub>3</sub>;  
10   7-NHCOCH<sub>3</sub>, NH<sub>2</sub>, Cl, Br or CF<sub>3</sub>;  
8-NHCOCH<sub>3</sub>, OH, OCH<sub>3</sub>, Cl, Br or CF<sub>3</sub>;  
9-OH, OCH<sub>3</sub>, Cl, Br, CF<sub>3</sub> or NO<sub>2</sub>;  
10-OH, OCH<sub>3</sub>, CF<sub>3</sub>, Cl, Br or NO<sub>2</sub>;  
11-NHCOCH<sub>3</sub>, Cl, OH, or OCH<sub>3</sub>.

15           The CF<sub>3</sub> derivative is prepared from its corresponding  
bromo or chloro substituent by treatment with CF<sub>3</sub>CO<sub>2</sub>Na and  
CuI, according to established techniques known in the art.

20

25

30

35

- 33 -

Example 32

1 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-5-nitro-3H-dibenz-  
(deh) isoquinoline-1,3-dione

5 A solution of 5-nitroindanone (Murray and Cromwell, J.  
Org. Chem. 41,3540 (1976)) in ethanol is treated with sodium  
borohydride followed by triphenylphosphine dibromide to  
furnish 1-bromo-5-nitroindan, which is converted into a  
Grignard reagent by magnesium in ether. Addition of  
10 2-cyclohexenone and cuprous iodide gives 1-(cyclohexanon-3-  
yl)-5-nitroindan. Conversion of this product into its  
hydroxymethylene derivative by ethyl formate and sodium  
ethoxide, followed by cyclization in the presence of  
polyphosphoric acid affords 7-nitro-4-oxo-1,2,3,4,8b, 11a-  
15 hexahydrocyclopentanoanthracene, which gives  
3-nitro-1,9-cyclopentanoanthracene on reduction with sodium  
borohydride followed by treatment with dichloro-  
dicyanobenzquinone. Oxidation of this product with sodium  
dichromate, followed by acidification, furnishes 5-  
20 nitroanthracene-1,9-dicarboxylic acid anhydride. Reaction  
of said anhydride with N,N-dimethylethylene diamine in  
accordance with the procedure described in Example 2 affords  
the above-identified product.

25

30

35



Example 33

1 5-Amino-2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz-  
(deh) isoquinoline-1,3-dione

5 The title compound is prepared by reducing the product  
prepared in Example 32 with hydrogen on palladium in  
accordance with the procedure described in Example 12.

10

15

20

25

30

35

Example 34

1

5-Acetamido-2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-  
dibenz(deh)isoquinoline-1,3-dione

5

The title compound is prepared by treating the  
corresponding 5-amino derivative prepared in Example 33 with  
acetic anhydride in pyridine.

10

15

20

25

30

35

The compounds of the present invention were tested for anti-tumor activity in various model systems.

These models included the following:

1) In vitro tumor colony forming assays in soft agar with murine and human tumor cell lines and with fresh human tumors.

2) In vitro tumor cell viability assays using MTT dye reaction endpoints.

3) In vitro survival studies in mice bearing solid flank tumors or hematologic malignancies in the peritoneum.

For example, the compounds of the present invention were evaluated for cytotoxic activities in cloned human colon carcinomas. The clonogenic assays were conducted in accordance with the procedure described hereinbelow:

1) Colony Forming Assays in Soft Agar: Fresh human or murine tumors are disaggregated into single cell suspensions using mechanical, hypoosmotic and/or enzymatic (trypsin) methods. The single cells (about  $5 \times 10^4$ - $10^5$ ) are plated in 35 mm plastic petri dishes onto a 1 ml "feeder layer" of 0.3% agar dissolved in growth medium containing 5-10% vol/vol of heat-inactivated fetal bovine serum, molten 0.3% agar and the antibiotics penicillin (100 u/mL) and streptomycin (100 ug/mL). Drug exposures can be performed for one hour or continuously (drugs added to final plating medium). Tumor cell colonies > 60 uM in size are counted by automated image analysis after 10-20 days of incubation in a humidified, 5-10% CO<sub>2</sub>-gassed environment maintained at 37°C. Inhibition of colony formation is calculated based on comparisons to control (untreated) plates wherein the growth of hundreds of colonies/plate is typical. (Salmon SE, et al., N Engl J Med 298(24):1321-1327, 1978).

The results are indicated in the following tables.

1

Table 1. Activity of Compounds Against Tumor Cells

Concentration ( $\mu$  molar) for 50% inhibition of colony  
formation for human colon tumors

5

	<u>compd</u>	<u>LOVOp32</u>	<u>205p14</u>	<u>SW80p105</u>	<u>HT29p30</u>
	1	0.3	0.4	0.15	0.34
10	2	3.0	3.0	2.5	1.75
	3	4.0	2.6	3.1	3.6
	7	0.75	10.0	1.0	4.4
	8	1.0	11.7	0.9	2.6
	9	5.6	17.5	3.0	11.25
15	10	NA	NA	0.75	0.25
	11	1.6	13.5	1.3	8.3
	12	0.8	11.5	1.3	8.3
	Amonafide (control)	0.6	0.16	0.57	0.96

20

-----

MTT assay with cells plated 24 hr. prior to drug addition. 3 day  
drug exposure.

25

NA = not active at concentration tested

30

35

1

Table 1a. Activities of Compounds Against Sensitive and Multidrug Resistant L1210 Leukemia Cells

5

Concentration (pg/ml) for 50% inhibition of tumor cells

10

15

20

Compound	Sensitive L1210	Resistant L1210
1	0.0025	0.0025
13	0.0027	0.003
14	5.0	----
15	0.0031	0.0031
16	0.0025	0.002
17	0.028	0.03
19	0.003	0.003
20	0.0032	0.0028
21	0.0032	0.0032
22	0.0032	0.0027

Six day MTT assay, continuous drug exposure

25

30

35

Compounds of the present invention were tested for their  
1 in vitro activity in tumor cells sensitive and resistant to  
standard anti-cancer agents. The tumor cell lines used in  
this protocol are 8226 Human Myeloma<sup>1</sup>; 8226/Dox-40<sup>2</sup>,  
L-1210/Murine Leukemia, multidrug resistant L-210/<sup>3</sup>, 2780  
Human Ovarian Cancer and 2780/AD<sup>4</sup>.

5 Each of these resistant cell lines is known as a  
multidrug resistant or "MDR" cell line. These cell lines  
produce a 170,00 molecular weight membrane protein termed  
the P-glycoprotein which acts as an active drug efflux pump.  
10 Thus, once a cell produces the P-glycoprotein, it has the  
capability of pumping out of the cell a large variety of  
unrelated natural products. These include some of our most  
active standard agents such as doxorubicin (adriamycin),  
vinca alkaloids (such as vincristine and vinblastine) and  
15 other DNA binders such as actinomycin D and daunomycin. The  
protocol for measuring the effectiveness of compounds of the  
present invention is as follows:

2) In Vitro Tumor Cell Viability Assays Using  
20 MTT-Dye: Tumors are processed into a single cell suspension  
as described above. The cells are plated at a concentration  
of  $3-5 \times 10^4$ /1 mL well into plastic 96-well plates. Growth  
medium containing 5-10% (vol/vol) heat-inactivated fetal  
bovine serum and penicillin/streptomycin (as above) is added  
prior to incubation at 37°C for six days. Afterwards the  
25 medium containing the drug is removed, the cells are  
"washed" by centrifugation in fresh medium or phosphate-  
buffered saline (pH 7.4). A tetrazolium dye is then added  
(3,4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide  
(MTT). This dye forms a colored formazan product upon  
30 activation by mitochondrial reductases in viable cells.

---

1. Matsuoka, Y, et al. Proc Soc Exptl. Biol. Med., 125,  
1246-1250 (1967).

2. Dalton, W.S., et al. Cancer Research, 46, 5125-5130  
(1986).

3. Dorr, et al., Biochem. Pharmacol., 36, 3115-3120  
35 (1980).

4. Rogan, A.M., et al., Science, 224, 994-996 (1984).

Typically, the formazan product is solubilized in  
acid-propanol or DMSO. The intensity of the color is  
proportional to viable cell numbers and this is quantitated  
by spectrophotometric absorbance (570 nM) on a micro ELISA  
plate reader. Test results are calibrated in % control  
absorbance from untreated tumor cells (Mossman T: J Immunol  
Meth 65:55-63, 1983).

10

15

20

25

30

35

Using the above procedure, Compound 1 was tested for its cytotoxic activity with respect to various tumor cell lines. The results are indicated hereinbelow in Table 2.

TABLE 2

In Vitro Cytotoxic Activity Insensitive and Multidrug Resistant Tumors\*

Tumor Cell Line	Resistance Spectrum	CMPD 1 Activity (IC <sub>50</sub> In ug/mL	CMPD 1 Cross Resistance
8226 Human Myeloma	Multidrug resistant, P-glycoprotein positive	.011	3-fold
8226/DOX-40	40-fold resistant to Doxorubicin	.036	
L-1210/Murine Leukemia		.003	
L-1210/	MDR, P-glycoprotein (+) 10-fold resistance to Mitomycin C	.003	None
2780 Human Ovarian Cancer		4.0	None
2780/AD	MDR, P-glycoprotein (+) 10-fold resistance to Doxorubicin	2.7	

\*4-day drug exposure in multiwell plastic plates; cell viability measured MTT dye reduction (N.C.I. method).



Table 2 shows that Compound 1 maintained anti-tumor activity against these multidrug resistant tumors in vitro. The only instance in which Compound 1 did not appear to completely maintain its activity was with the DOX 40 cell line where a possible three-fold cross resistance was evident. However, this is a highly artificial level of resistance (i.e., 40-fold resistance is not seen commonly in the clinic). Thus, in the lower level resistant cell lines, such as the ten-fold mitomycin C resistant L1210 and the tenfold adriamycin resistant 2780 ovarian cancer, Compound 1 maintained its complete activity as shown in Table II.

The anti-tumor activity of compounds of the present invention in in vivo mouse murine models were studied.

### 3) Survival Studies In Tumor-Bearing Mice:

3.1 P-388 Leukemia Modles: One million P-388 leukemia cells originally obtained from American Type Culture Collection (Rockville, MD) are implanted into the peritoneum of adult DBA-2J male mice (Jackson Laboratories, Bar Harbor, ME). Twenty four hours later, drugs diluted in physiological saline are injected intraperitoneally at a volume of 0.1 mL/10 g body weight. The mice (10/group) are then followed for survival daily and compared to untreated tumor bearing mice. Survival results are converted to a percent increased lifespan over untreated controls (Geran RI, et al., Cancer Chemo Rep., 3, 1-10, 1972).

P-388/Adriamycin Resistant Cells: The same protocol as above was used for these studies with a multidrug resistant P-388 cell line developed in vivo by and supplied by Dr. Randall Johnson (John RK, et al., Cancer Treat Rep 62, 1535-1547, 1978).

Colon-38: Freshly-harvested 20-30 mg pieces of viable colon-38 adenocarcinoma are injected into the right front flank of C57/B1 adult mice. These tumors are allowed to grow for three days. Drugs are injected intraperitoneally on days three and six after inoculation at a volume of 0.1 mL/10 g body weight. The perpendicular widths of the tumors are measured by caliper thrice weekly and converted to an estimated tumor mass according to the formula:  $\frac{1}{2} \times W^2 =$

grams of tumor.

1

wherein

W = width of tumor

5

l = length of tumor

Tumor growth delay is calculated as the difference in days for tumors in treated mice to reach an estimated mass 750 mg or 1.5 g compared to that in untreated controls:

10

Days to reach 750 mg (Treated - Control) = Days of Tumor  
Growth Delay

Corbett, T.H., et al., Cancer Chemo Rep., 5 (1975).  
Mammary 16-C Adenocarcinoma and M5-76 Sarcoma:

15

Chunks of tumor (20-50 mg) are subcutaneously implanted into the flank of B6C3F1 female mice. Drugs (10-45 mg/kg) are dissolved in saline and injected intraperitoneally every four days for three times starting one day after tumor implantation. Tumors are measured bidimensionally as described above and tumor growth delay is calculated at times to reach 1.5 and 3.0 g of tumor mass.

20

25

Using the various in vivo mouse models and the procedures described hereinabove, the anti-tumor activity of compound 1 was tested. The results are shown in Table 3 hereinbelow.

30

35

TABLE 3

ANTI-TUMOR ACTIVITY OF COMPOUND 1 in in vivo MOUSE MODELS

Tumor Cell Line	Model	Drug Regimen (mg/kg X days)	Experimental Activity	Comparative Activity From The Literature		
				Amonafide	Doxorubicin	T-AMSA
P-388 lymphocytic leukemia	10 <sup>6</sup> cells in DBA mice	16; dl,5,9	00:ILS*	99 ILS	164 ILS	124 ILS
P-388/ADR (adriamycin-Resistant)	10 <sup>6</sup> cells in DBA mice	15; dl,5,9	33 ILS	35 ILS	18 ILS	unk.**
Colon-38 Adenocarcinoma	20mg implants in C <sub>57</sub> B/mice	15; d3,6	6 days TT	<7 days	10 days	2 days
16-C Mammary Adenocarcinoma	(Southern Research Institute)	----	7 days TT	7 days	unk.	unk.
76 Sarcoma	(Southern Research Institute)	----	7 days	7 days	unk.	unk.

ILS = Percentage Increased Lifespan  
T Days of Tumor Growth Delay

\* Unknown

1 Drug deaths: a treated, tumored animal was presumed to die  
of drug toxicity if its day of death was significantly  
earlier than the corresponding day of death in the untreated  
control group and its tumor was less than 550 mg, or if it  
dies with a tumor of 550 mg or less prior to 45 days after  
the last day of treatment, or if the treated animal was  
5 uniquely specified as a drug death on data input. T-C  
excludes drug deaths, tumor free survivors and any other  
animal whose tumor failed to obtain the evaluation size and  
is the unweighted average of the differences of the median  
times post implant for the treated and control groups to  
10 attain each of the two evaluation sizes.

#### Evaluation of Tumor Growth

15 The appearance of tumors of a threshold size, and the  
growth in these tumors in groups of 10 mice (B6C3F0, 18-22 g)  
implanted with  $5 \times 10^6$  M5076 carcinoma cells compared to the  
tumor appearance and growth in samples treated with NSC308847  
and Compound 1 are shown in Table 3. The values are median  
20 values for the samples, and show the weight of the tumor  
with time.

These studies confirm that the compound of this  
invention delays the appearance of tumors at the threshold  
level significantly over the control and similarly to the  
comparative drug (amonafile) at the same dose level, and  
25 significantly reduces the tumor growth at lower dose rates.

The cytotoxic activity of compounds of the present  
invention in fresh human tumors was also tested. The  
protocol is as follows:

30 Fresh human tumor specimens disaggregated to single  
cell suspensions and exposed to .001 ug/mL of drug

continuously. Percent survival represents the fraction of  
tumor colonies ( $> 60 \mu\text{M}$  size) obtained after drug treatment  
1 compared to untreated cells of the same tumor. Overall  
sensitivity indicates tumor cell survival of less than 50%  
of control colony-forming cells. Each tumor sample is  
5 analyzed in three different petri dishes (i.e.,  $n = 3$  for  
each sample).

10

15

20

25

30

35

The results are indicated in Table 4

Table 4

CYTOTOXIC ACTIVITY FOR COMPOUND 1 IN FRESH HUMAN TUMORS<sup>1</sup>

Human Tumor Type	<u>Compound 1 Sensitive</u> <u>&lt;30-50%</u>		<u>Doxorubicin Sensitive<sup>2</sup></u> <u>&lt;30-50%</u>			Overall Response	No. of Samples	<30% Control	of Control	Overall Response
	No. of Samples	<30% Control	of Control	Overall Response	No. of Samples					
Breast	11	3	4	64%	58	6	5			19%
Colon/Rectum	7	8	1	14%	17	3	2			29%
Lung	6	2	1	50%	12	1	1			17%
Melanoma	11	4	3	64%	10	0	0			0
Ovary	<u>8</u>	<u>3</u>	<u>1</u>	<u>50%</u>	<u>36</u>	<u>2</u>	<u>7</u>			<u>25%</u>
Total	43	12	10	51%	133	12	15			20%

<sup>1</sup>Fresh human tumor specimens disaggregated to single cell suspensions and exposed to .001 ug/mL of drug continuously. Percent survival represents the fraction of tumor colonies (> 60 uM size) obtained after drug treatment compared to untreated cells of the same tumor. Overall sensitivity indicates tumor cell survival of less than 50% of control colony-forming cells. Each tumor sample is analyzed in three different petri dishes (i.e., n = 3 for each sample).

<sup>2</sup>Doxorubicin tumors were from different patients.

The data in Table 4 results from testing on a group of human tumors, totalling 43 separate human cancers. The overall response rate in these 43 samples was 51% using a continuous drug concentration of (.001 ug/mL). These data represent a very high level of in vitro activity; some of the highest levels of activity were seen in typically adriamycin-responsive tumors such as breast cancer and ovarian cancer. Unexpected was the level of activity of compound 1 against melanomas (64%). Melanoma is widely known to be an extremely chemoresistant disease with most standard agents.<sup>5</sup> The data shows that compared to doxorubicin (overall response rate of 20%), compound 1 was significantly superior.

Other compounds were tested and the in vitro cytotoxic activity in accordance with the procedure described hereinabove with respect to Table 2. The results are indicated hereinbelow in Table 5.

TABLE 5

IN VITRO CYTOTOXIC ACTIVITYIC<sub>50</sub> VALUES (ng/ML CONTINUOUS EXPOSURE)\*

Compound #	8226 Myeloma Cells		L1210 Leukemia Cells	
	Sensitive	Resistant	Sensitive	Resistant
1	10	30	2.8	2.5
13	5	10	2.5	2.9
14	>100	>100	5,000	>5,000

\*Measured by MTT dye assay (N.C.I. Method).

<sup>5</sup> Luce, J.K., Seminar Oncol, 2, 179-185 (1975).

The above preferred embodiments and examples are given to illustrate the scope and spirit of the present invention. These embodiments and examples will make apparent, to those skilled in the art, other embodiments and examples. These other embodiments and examples are within the contemplation of the present invention. Therefore, the present invention should be limited only by the appended claims.

10

15

20

25

30

35




1 WHAT IS CLAIMED IS:

1. A compound of the formula:

5

10



15

wherein

20  $R_8$ ,  $R_6$  and  $R_{10}$  are independently hydrogen, lower alkyl, aryl, lower alkanoyl, formyl, halogen, nitro,  $\text{NR}_2\text{R}_3$ ,  $\text{OR}_1$ , or  $\text{SR}_1$ , hydroxy, methoxy, cyano,  $\text{CO}_2\text{H}$ ,  $\text{SO}_2\text{NR}_1\text{R}_2$ , or  $\text{CONR}_1\text{R}_2$ ;

$R_1$ ,  $R_2$  and  $R_3$  are independently hydrogen, lower alkyl, aryl lower alkyl, aryl, formyl or lower alkanoyl;

25  $R_9$ ,  $R_{11}$ ,  $R_{10}$  and  $R_7$  are indendently hydrogen, or lower alkyl or

$R_9$  and  $R_{11}$  taken together with the carbon atoms to which they are attached form a phenyl group or

$R_9$  and  $R_{10}$  taken together with the arbon atoms to which they are attached form a phenyl group or

30  $R_7$  and  $R_{10}$  taken together with the carbon atoms to which they are attached form a phenyl group;

A is  $(\text{CR}_4\text{R}_5)_3$ , lower cycloalkyl or aryl or a chemical bond;

35

1        each  $R_4$  and  $R_5$  are independently hydrogen or lower alkyl;  
       $R_{12}$  and  $R_{13}$  are independently hydrogen, or lower alkyl  
      which is unsubstituted or substituted with hydroxy,  
      mercapto, lower alkoxy, lower alkylcarbonyloxy, carboxy, or  
5        carbloweralkoxy or  $R_{12}$  and  $R_{13}$  taken together with the  
      nitrogen to which they are attached form a 3-6-membered  
      heterocyclic ring;

      D is a chemical bond, or taken together with  $NR_{12}$  form  
      a 5 or 6-membered heterocyclic ring;

10         $n_1$  and  $n_2$  are independently 0, 1 or 2; and  
       $n_3$  is 0, 1, 2, 3, 4 or 5.

      2. The compound according to Claim 1 wherein  
       $R_9$ ,  $R_{11}$ ,  $R_{10}$ ,  $R_7$  and  $R_8$  are hydrogen.

15        3. The compound according to Claim 1 or 2  
      wherein  $R_6$  is hydrogen, amino, nitro, hydroxy or halo and  
      n is 1.

20        4. The compound according to Claim 3 wherein  $R_6$   
      is 8-nitro, 8-amino, 11-nitro or 11-amino.

      5. The compound according to any of Claims 1 to  
      4 wherein A is aryl or  $(CR_4R_5)_3$  and D is a chemical bond.

25        6. The compound according to Claim 5 wherein  $n_3$  is  
      2-4.

      7. The compound according to Claim 6 wherein  $R_4$  and  $R_5$   
      are independently hydrogen.


30        8. The compound according to Claim 1 wherein  $R_{10}$  is  
      hydrogen, methyl, chloro, methoxy or hydroxy.

35

1        9. The compound according to Claim 1 wherein  $R_{12}$  and  $R_{13}$  are hydrogen or lower alkyl unsubstituted or substituted with hydroxy. ,

5        10. The compound according to Claim 1 wherein  $R_{12}$  and  $R_{13}$  are the same.

11. The compound according to claim 1 wherein D taken together with  $NR_{12}$  form a 5 or 6-membered nitrogen containing  
10 ring.



13. The compound according to Claim 11 wherein  
20  $R_{12}$  and  $R_{13}$  taken together with the nitrogen to which they are attached form a pyrrolidine or a piperidine ring.

25

30

35

14. The compound according to Claim 1 which is

1 2-[2'-(N-pyrrolidino)ethyl]-1,2-dihydro-3H-dibenz(deh)-  
isoquinoline-1,3-dione, 2-[2'-(N-piperidino)ethyl]-1,2-  
dihydro-3H-dibenz(deh)isoquinoline-1,3-dione,  
2-[1'-ethyl-3'-piperidinyl]-1,2-dihydro-3H-dibenz(deh)-  
5 isoquinoline-1,3-dione, 2-[3'-(Bis-β-hydroxyethyl)amino-  
propyl]-1,2-dihydro-3H-dibenz(deh)isoquinoline-1,3-dione,  
2-[3'-(dimethylamino)propyl]-1,2-dihydro-3H-dibenz(deh)-  
isoquinoline-1,3-dione, 2-(4'-dimethylaminophenyl)-1,2-  
10 dihydro-3H-dibenz(deh)isoquinoline-1,3-dione,  
2-[2'-(dimethylamino)ethyl]-1,2-dihydro-11-nitro-3H-dibenz-  
(deh)isoquinoline-1,3-dione, 8-amino-2-[2'-dimethylamino-  
ethyl]-1,2-dihydro-3H-dibenz(deh)isoquinoline-1,3-dione,  
11-amino-2-[2'-(dimethylaminoethyl)-1,2-dihydro-3H-dibenz-  
(deh)isoquinoline-1,3-dione, 2-[2'-(dimethylamino)ethyl]-  
15 6-ethyl-1,2-dihydro-3H-dibenz(deh)isoquinoline-1,3-dione,  
7-chloro-2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz-  
(deh)isoquinoline-1,3-dione,  
2-[2'-(1-piperazinyl)ethyl]-1,2-dihydro-3H-dibenz(deh)isoquin-  
oline-1, 3-dione;  
20 2-[2'-(N-morpholinyl)ethyl]-1,2-dihydro-3H-dibenz(deh)-  
isoquinoline-1, 3-dione;  
2-[(1'-ethyl-2-pyrrolidinyl)methyl]-1,2-dihydro-3H-dibenz-  
(deh)isoquinoline-1, 3-dione;  
2-[2'-(1-methyl)-2-pyrrolidinyl)ethyl]-1,2-dihydro-3H-dibenz-  
25 (deh)isoquinoline-1, 3-dione;  
2-[(3'-piperidinyl)methyl]-1,2-dihydro-3H-dibenz(deh)-  
isoquinoline-1, 3-dione;  
2-(3'-pyridyl)-1,2-dihydro-3H-dibenz(deh)isoquinoline-  
1,3-dione;  
30 2-[2'-(2-pyridyl)ethyl]-1,2-dihydro-3H-dibenz(deh)-  
isoquinoline-1, 3-dione and;  
2-[(1'-aziridinyl)ethyl]-1,2-dihydro-3H-dibenz(deh)-  
isoquinoline-1, 3-dione.

1

15. The compound according to Claim 1 which is

2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz-  
(deh)isoquinoline-1,3-dione

5

2-[2'-(dimethylamino)ethyl]-1,2-dihydro-8-nitro-3H-dibenz-  
(deh)isoquinoline-1,3-dione

2-[2'-(dimethylamino)ethyl]-1,2-dihydro-6-ethyl-3H-dibenz-  
(deh)isoquinoline-1,3-dione

10

10-chloro-2-[2'-(dimethylamino)ethyl]-1,2-dihydro-  
3H-dibenz(deh)isoquinoline-1,3-dione

2-[2'-(dimethylamino)ethyl]-1,2-dihydro-7-hydroxy-3H-dibenz-  
(deh)isoquinoline-1,3-dione

2-[2'-(Dimethylamino)ethyl]-1,2-dihydro-7-methoxy-3H-dibenz-  
(deh)isoquinoline-1,3-dione

15

2-[2'-(Dimethylamino)ethyl]-1,2-dihydro-7-methyl-3H-dibenz-  
(deh)isoquinoline-1,3-dione

1,2-Dihydro-2-[2'-methylaminoethyl]-3H-dibenz(deh)-  
isoquinoline-1,3-dione

20

25

30

35

- 1 4-acetamido-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-3H-dibenz(deh)isoquinoline-1,3-dione;  
4-amino-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-3H-dibenz(deh)isoquinoline-1,3-dione;
- 5 4-hydroxy-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-3H-dibenz(deh)isoquinoline-1,3-dione;  
4-methoxy-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-3H-dibenz(deh)isoquinoline-1,3-dione;  
4-chloro-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-3H-
- 10 dibenz(deh)isoquinoline-1,3-dione;  
4-trifluoromethyl-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-3H-dibenz(deh)isoquinoline-1,3-dione;  
5-acetamido-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-3H-dibenz(deh)isoquinoline-1,3-dione;
- 15 5-amino-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-3H-dibenz(deh)isoquinoline-1,3-dione;  
5-methoxy-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-3H-dibenz(deh)isoquinoline-1,3-dione;  
5-nitro-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-3H-
- 20 dibenz(deh)isoquinoline-1,3-dione;  
6-acetamido-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-3H-dibenz(deh)isoquinoline-1,3-dione;  
6-amino-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-3H-dibenz(deh)isoquinoline-1,3-dione;
- 25 6-hydroxy-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-3H-dibenz(deh)isoquinoline-1,3-dione;  
6-methoxy-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-3H-dibenz(deh)isoquinoline-1,3-dione;  
6-chloro-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-3H-
- 30 dibenz(deh)isoquinoline-1,3-dione;  
6-trifluoromethyl-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-3H-dibenz(deh)isoquinoline-1,3-dione;  
6-nitro-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-3H-dibenz(deh)isoquinoline-1,3-dione;

- 1 6-methyl-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-3H-  
dibenz(deh)isoquinoline-1,3-dione;  
7-acetamido-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-3H-  
dibenz(deh)isoquinoline-1,3-dione;
- 5 7-amino-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-3H-  
dibenz(deh)isoquinoline-1,3-dione;  
7-trifluoromethyl-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-  
3H-dibenz(deh)isoquinoline-1,3-dione;  
7-methylthio-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-3H-
- 10 dibenz(deh)isoquinoline-1,3-dione;  
8-acetamido-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-3H-  
dibenz(deh)isoquinoline-1,3-dione;  
8-hydroxy-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-3H-  
dibenz(deh)isoquinoline-1,3-dione;
- 15 8-methoxy-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-3H-  
dibenz(deh)isoquinoline-1,3-dione;  
8-chloro-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-3H-  
dibenz(deh)isoquinoline-1,3-dione;  
8-trifluoromethyl-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-
- 20 3H-dibenz(deh)isoquinoline-1,3-dione;  
9-acetamido-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-3H-  
dibenz(deh)isoquinoline-1,3-dione;  
9-amino-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-3H-  
dibenz(deh)isoquinoline-1,3-dione;
- 25 9-hydroxy-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-3H-  
dibenz(deh)isoquinoline-1,3-dione;  
9-methoxy-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-3H-  
dibenz(deh)isoquinoline-1,3-dione;  
9-chloro-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-3H-
- 30 dibenz(deh)isoquinoline-1,3-dione;  
9-trifluoromethyl-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-  
3H-dibenz(deh)isoquinoline-1,3-dione;  
9-nitro-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-3H-  
dibenz(deh)isoquinoline-1,3-dione;

- 1 10-acetamido-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-3H-  
dibenz(deh)isoquinoline-1,3-dione;  
10-amino-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-3H-  
dibenz(deh)isoquinoline-1,3-dione;
- 5 10-hydroxy-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-3H-  
dibenz(deh)isoquinoline-1,3-dione;  
10-methoxy-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-3H-  
dibenz(deh)isoquinoline-1,3-dione;  
10-trifluoromethyl-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-  
3H-dibenz(deh)isoquinoline-1,3-dione;
- 10 10-nitro-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-3H-  
dibenz(deh)isoquinoline-1,3-dione;  
11-acetamido-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-3H-  
dibenz(deh)isoquinoline-1,3-dione;
- 15 11-hydroxy-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-3H-  
dibenz(deh)isoquinoline-1,3-dione; or  
11-methoxy-2-[(2'-dimethylamino)ethyl]-1,2-dihydro-3H-  
dibenz(deh)isoquinoline-1,3-dione;
- 20 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-5-nitro-3H-  
debenz(deh)isoquinoline,  
5-amino-2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-  
dibenz(deh)isoquinoline-1,3-dione; or  
5-acetamido-2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-  
dibenz(deh)isoquinoline-1,3-dione.

25

30

35



1           16. A pharmaceutical composition for the  
treatment of tumors comprising an anti-tumor effective  
amount of a compound according to any of Claims 1 to 15  
and a pharmaceutical carrier therefor.

5           17. A compound as defined in any of Claims 1 to  
15 for preparing a composition useful for treating tumors.

10

15

20

25

30

35

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/US91/04364

## I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) \*

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC(5): C07D 221/18, 401/04,06, 409/04,06; A61K 31/44,495,535

US CL.: 544/125,238,333,361,405; 546/76; 514/232.8,253,256,284

## II. FIELDS SEARCHED

Minimum Documentation Searched <sup>7</sup>

Classification System

Classification Symbols

US

544/125,238,333,361,405; 546/76; 514/232.8,253,256,284

Documentation Searched other than Minimum Documentation  
to the Extent that such Documents are Included in the Fields Searched \*

## III. DOCUMENTS CONSIDERED TO BE RELEVANT \*

Category *	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
A	US, A, 4,665,071 (ZEE-CHENG et al.) 12 May 1987 See abstract.	1-17
A	US, A, 3,940,398 (WADE et al.) 24 February 1976 See abstract.	1-16
A	US, A, 1,253,252 (KARDOS et al.) 15 January 1918 See column 2.	1-16

\* Special categories of cited documents: <sup>10</sup>

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

## IV. CERTIFICATION

Date of the Actual Completion of the International Search

12 SEPTEMBER 1991

Date of Mailing of this International Search Report

03 OCT 1991

International Searching Authority

ISA/US

Signature of Authorized Officer

PHILIP L. DATLOW  
INTERNATIONAL DIVISION